MARATTO

article · Journal of Applied Toxicology

Luteolin‐Loaded Chitosan Nanoparticles Attenuate Fenvalerate‐Induced Nephrotoxicity and Humoral Immune Suppression via NRF2/HO‐1 Activation and NF‐κB‐Mediated Inflammatory and Apoptotic Pathway Inhibition

Abstract

Fenvalerate (FEV), a widely used pyrethroid, induces renal toxicity and suppresses humoral immunity. This study evaluated the protective effects of crude luteolin (LUT) and LUT-loaded chitosan nanoparticles (LUT-CHNPs) in male Wistar rats. The research included 60 rats divided into six groups: control, LUT, LUT-CHNPs, FEV, FEV + LUT, and FEV + LUT-CHNPs and administered oral treatment for a duration of 30 days. Exposure to FEV elevated levels of renal biomarkers, oxidative stress markers, pro-inflammatory cytokines, apoptotic proteins, and complement C3. It also reduced levels of antioxidant enzymes, GSH, NRF2/HO-1 expression, Bcl-2, and immunoglobulins (IgG, IgM). The concurrent administration of LUT-CHNPs significantly enhanced these alterations, restoring renal function, oxidative balance, anti-inflammatory and anti-apoptotic mechanisms, and humoral immunity. Histopathological and ultrastructural analyses confirmed the preservation of glomerular and tubular architecture, mitochondrial integrity, and organization of apical microvilli with LUT-CHNPs, indicating superior efficacy relative to crude LUT. The findings indicate that LUT-CHNPs enhance drug bioavailability and safeguard the kidneys and immune system against FEV-induced nephrotoxicity and immune suppression.

Research topics

  • Chemotherapy-induced organ toxicity mitigation
  • Inflammasome and immune disorders
  • Paraquat toxicity studies and treatments

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1002/jat.70141

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.